Use of heparinases to decrease inflammatory response

Details Use of heparinases to decrease inflammatory response Use of heparinases to decrease inflammatory response

2007-09-04

2007-09-04

Chan, Christina (Department: 1644)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Transferases

C424S094100, C424S810000, C435S232000, C514S002600

Reexamination Certificate

active

11357967

ABSTRACT:
Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 5169772 (1992-12-01), Zimmerman et al.
patent: 5340800 (1994-08-01), Liu et al.
patent: 5362641 (1994-11-01), Fuks et al.
patent: 5567417 (1996-10-01), Sasisekharan et al.
patent: 5714376 (1998-02-01), Sasisekharan et al.
patent: 5789182 (1998-08-01), Yayon et al.
patent: 5997863 (1999-12-01), Zimmermann et al.
patent: 88/05301 (1988-07-01), None
patent: WO-91/07760 (1991-05-01), None
patent: WO-95/00171 (1995-01-01), None
Bargatze et al., “Rapid G Protein-regulated Activation Event Involed in Lymphocyte Binding to Hight Endothelian Venules” The Journal of Experimental Medicine, vol. 178, pp. 367-373 (1993).
Bohn et al., “Fragmentation of Heparin by Enzymes from Newly Isolated Microorganisms” Drug Res. 41(1), Nr. 4, pp. 456-460 (1991).
Brach et al., “Leukotriene B4Transcriptionally Activates Interleukin-6 Expression Involving NK-χB and NF-IL6*” Eur. J. Immunol., vol. 22, pp. 2705-2711, (1992).
Butcher, “Leukocyte-Endothelian Cell Recognition: Three (or More) Steps to Specificity and Diversity” Cell, 67, pp. 1033-1036 (1991).
Carlos et al., “Leukocyte-Endothelial Adhesion Molecules” Blood, vol. 84, No. 7, pp. 2068-2101 (1994).
Carlos et al., “Membrane Proteins Involved in Phagocyte Adherence to Endothelium” Immunol. Rev., No. 114,pp. 5-28 (1990).
Cohen et al., “Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation ofEscherichia coliby R-Factor DNA*” Proc. Natl. Acad. Sci., vol. 69, No. 8, pp. 2110-2114 (1972).
Delgado et al., “The Uses and properties of PEG-Linked Proteins” Critical Rev. Ther. Drug Carrier Syst. vol. 9, Nos. 3-4, pp. 249-304 (1992).
Dustin et al., “Induction by IL 1 and Interferon-γ: Tissue Distribution, Biochemistry, and Function of a Natural Adherence Molecule (ICAM-1)1” J. Immunol., vol. 137, No. 1, pp. 245-254 (1986).
Ebisawa et al., “Eosinophil Transendothelial Migration Induced by Cytokines” J. Immunol., vol. 149, No. 12, pp. 4021-4028 (1992).
Finn et al., “Interleukin-8 Release and Neutrophil Degranulation After Pediatric Cardiopulmonary Bypass” J. Thorac. J. Surg., vol. 105, No. 2, pp. 234-241 (1993).
Galliher et al., “Heparinase Production by Flavobacterium Hepanium” Appl. Environ. Microbiol., vol. 41, No. 2, pp. 360-365 (1981).
Hanahan et al., “Platelet Activating Factor: A Biologically Active Phosphoglyceride” Ann. Rev. Biochem., vol. 55, pp. 283-509, (1986).
Harlan, “Leukocyte Adhesion Deficiency Syndrome: Insights into the Molecular Basis of Leukocyte Emigration” Clin. Immunol. Immunopath., vol. 67, No. 3, pp. S16-S24, (1993).
Hoogewerf et al., “CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 are Heparin/Heparan Sulfate-degrading Enxymes*” J. Biol. Chem., vol. 270, No. 7, pp. 3268-3277 (1995).
Hoover et al., “Leukotriene B4Action on Endothelium Mediates Augmented Neutrophil/Endothelial Adhesion” Proc. Natl. Acad. Sci. USA, vol. 81, pp. 2191-2193 (1984).
Huber et al., “Regulation of Transendothelial Neutrophil Migration by Endogenous Interleukin-8” Science, vol. 254, pp. 99-102 (1991).
Huber et al., “Disruption of the Subendothelial Basement Membrane During Neutrophil Diapedesis in an In Vitro Construct of a Blood Vessel Wall” J. Clin. Invest., vol. 83, pp. 1122-1136 (1989).
Hughes et al., “Role of Leukotriene B4in the Pathogenesis of Hepatic Ischemia-Reperfusion Injury in the Rat” Prost. Leuk. Essent. F. A., vol. 45, pp. 113-119 (1992).
Jeannin et al., “Histamine Induces Interleukin-8 Secretion by Endothelial Cells” Blood, vol. 84, No. 7, pp. 2229-2233 (1994).
Jutila et al., “Function and Regulation of the Neutrophil Mel-14 Antigen in Vivo: Comparison With LFA-1 and MAC-11” J. Immunol., vol. 143, No. 10, pp. 3318-3324 (1989).
Kishimoto et al., “Neutrophil Mac-1 and MEL-14 Adhesion Proteins Inversely Regulated by Chemotactic Factors” Science, vol. 245, vol. 1238-124 (1989).
Kuijpers et al., “Neutropil Migration Across Monolayers of Cytokine-Prestimulated Endothelial Cells: A Role for Platelet-Activating Factor and IL-8” J. Cell Biol., vol. 117, No. 3, pp. 565-572 (1992).
Lasky, “Combinatorial Mediators of Inflammation?” Current Biol., vol. 3, No. 6, pp. 366-368 (1993).
Ley, et al., “Sialylated O-Glycans and L-Selectin Sequentially Mediate Myeloid Cell Rolling In Vivo” Blood, vol. 85, No. 12, pp. 3727-3735 (1995).
Lindemann, et al., “Granulocyte-Macrophage Colony-Stimulating Factor Induces Cytokine Secretion by Human Polymorphonuclear Leukocytes” J. Clin. Invest., vol. 83, pp. 1308-1312 (1989).
Lindemann et al., “Granulocyte-Macrophage Colny-Stimulating Factor Induces Interleukin 1 Production by Human Polymorphonuclear Neutrophils1” J. Immunol., vol. 140, No. 3, pp. 837-839 (1988).
Lo et al. “Endothelial-Leukocyte Adhesion Molecule 1 Stimulates the Adhesive Activity of Leukocyte Integrin CR3 (CD11b/CD18, Mac-1, αmβ2)” J. Exp. Med., vol. 173, pp. 1493-1500 (1991).
Lohse et al., “Purification and Characterization of Heparin Lyases from Flavobacterium heparinum*” J. Biol. Chem., vol. 267, No. 34, pp. 24347-24355 (1992).
Lorant et al., “Coexpression of GMP-140 and PAF by Endothelium Stimulated by Histamine or Thrombin: A Juxtacrine System for Adhesion and Activation of Neutrophils” J. Biol. Chem., vol. 115, No. 1, pp. 223-234 (1991).
Lowell, et al., “Proteosome-Lipopeptide Vaccines: Enhancement of Immunogenicity for Malaria CS Peptides” Science, vol. 240, pp. 800-802 (1988).
Lu, et al., “Pegylated Peptides I: Solid-Phase Synthesis of Nα-Pegylated Peptides Using Fmoc Strategy” Pept. Res. Vo. 6, No. 3, 140-146 (1993).
Lukacs, et al., “Interleukin-1 Receptor Antagonist Blocks Chemokine Production in the Mixed Lymphocyte Reaction” Blood, vol. 82, No. 12, pp. 3668-3674 (1993).
Luscinaskas et al., “Inn Vitro Inhibitory Effect of IL-8 and Other Chemoattractants on Neutrophil-Endothelial Adhesive Interactions1” J. Immunol., vol. 149, No. 6, pp. 2163-2171 (1992).
Maccarana, et al., “Minimal Sequence in Heparin/Heparan Sulfate Required for Binding of Basic Fibroblast Growth Factor*” J. Biol. Chem., vol. 268, No. 32, pp. 23898-23905 (1993).
Matsushima, et al., “Interleukin-8 and MCAF: Nevel Leukocyte Recruitment and Activating Cytokines” Interleukins: Molec. Biol. Immunol., ed. Kistimoto, Karger, Basel, vol. 51pp. 236-265 (1992).
McCain, et al., “Leukotriene B4Stimulates Human Polymorphonuclear Leukocytes to Synthesize and Release Interleukin-8 In Vitro” Am. J. Respir. Cell Molec. Biol., vol. 10, pp. 651-657 (1994).
McCain, et al., “Granulocyte/Macrophage Colony-Stimulating Factor Stimulates Human Polymorphonuclear Leukocytes to Produce Interleukin-8 In Vitro” Am. J. Respir. Cell Molec. Biol., vol. 8, pp. 28-34 (1993).
McIntyre, et al., “Leukotri

Affiliated with

Also associated with

Rating

Use of heparinases to decrease inflammatory response does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of heparinases to decrease inflammatory response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of heparinases to decrease inflammatory response will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3750105